Yishan Zheng

Yishan Zheng

Auto-generated profile, based on publicly available information

Yishan Zheng

Biomaterials and Medical Devices Research Group, School of Pharmacy and Biomolecular Sciences, University of Brighton, Brighton, UK

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
SSSusan R. Sandeman
Susan R. Sandeman
Volodymyr M Gun'koVolodymyr M Gun'ko
Volodymyr M Gun'ko
OBOlga M. Bakalinska
Olga M. Bakalinska
CHCarol A. Howell
Carol A. Howell
YZYishan Zheng
Yishan Zheng
SMSergey Mikhalovsky
Sergey Mikhalovsky

1 September 2011 in Journal of Hazardous Materials
Verified
Journal Article
Closed access
Irina N. SavinaIrina N. Savina
Irina N. Savina
CEChristopher J. English
Christopher J. English
RWRaymond Whitby
Raymond Whitby
YZYishan Zheng
Yishan Zheng
ALAndre Leistner
Andre Leistner
ACAndrew B. Cundy
Andrew B. Cundy

1 May 2015 in Biomaterials
Verified
Journal Article
Open access
GIGanesh C. Ingavle
Ganesh C. Ingavle
LBLes Baillie
Les Baillie
YZYishan Zheng
Yishan Zheng
ELElzbieta K. Lis
Elzbieta K. Lis
Irina N. SavinaIrina N. Savina
Irina N. Savina
SSSusan R. Sandeman
Susan R. Sandeman
Polymeric cryogels are efficient carriers for the immobilization of biomolecules because of their unique macroporous structure, permeability, mechanical stability and different surface chemical functionalities. The aim of the study was to demonstrate the potential use of macroporous monolithic cryogels for biotoxin removal using anthrax toxin protective antigen (PA), the central cell-binding component of the anthrax exotoxins, and covalent immobilization of monoclonal antibodies. The affinity ligand (protein A) was chemically coupled to the reactive hydroxyl and epoxy-derivatized monolithic cryogels and the binding efficiencies of protein A, monoclonal antibodies to the cryogel column were determined. Our results show differences in the binding capacity of protein A as well as monoclonal antibodies to the cryogel adsorbents caused by ligand concentrations, physical properties and morphology of surface matrices. The cytotoxicity potential of the cryogels was determined by an in vitro viability assay using V79 lung fibroblast as a model cell and the results reveal that the cryogels are non-cytotoxic. Finally, the adsorptive capacities of PA from phosphate buffered saline (PBS) were evaluated towards a non-glycosylated, plant-derived human monoclonal antibody (PANG) and a glycosylated human monoclonal antibody (Valortim(®)), both of which were covalently attached via protein A immobilization. Optimal binding capacities of 108 and 117 mg/g of antibody to the adsorbent were observed for PANG attached poly(acrylamide-allyl glycidyl ether) [poly(AAm-AGE)] and Valortim(®) attached poly(AAm-AGE) cryogels, respectively, This indicated that glycosylation status of Valortim(®) antibody could significantly increase (8%) its binding capacity relative to the PANG antibody on poly(AAm-AGE)-protien-A column (p < 0.05). The amounts of PA which remained in the solution after passing PA spiked PBS through PANG or Valortim bound poly(AAm-AGE) cryogel were significantly (p < 0.05) decreased relative to the amount of PA remained in the solution after passing through unmodified as well as protein A modified poly(AAm-AGE) cryogel columns, indicates efficient PA removal from spiked PBS over 60 min of circulation. The high adsorption capacity towards anthrax toxin PA of the cryogel adsorbents indicated potential application of these materials for treatment of Bacillus anthracis infection.

4 April 2016 in Hemodialysis International
Verified
Journal Article
Closed access
PDF file
SKSakina Kandouz
Sakina Kandouz
AMAli Shendi Mohamed
Ali Shendi Mohamed
YZYishan Zheng
Yishan Zheng
SSSusan Sandeman
Susan Sandeman
ADAndrew Davenport
Andrew Davenport

1 February 2016 in Carbon
Verified
Journal Article
Open access
CHC.A. Howell
C.A. Howell
SSS.R. Sandeman
S.R. Sandeman
YZY. Zheng
Y. Zheng
SMSergey Mikhalovsky
Sergey Mikhalovsky
VNV.G. Nikolaev
V.G. Nikolaev
ESElisaveta Snezhkova
Elisaveta Snezhkova
Activated carbon (AC) can be used for blood purification (hemoperfusion) to treat a range of conditions by direct perfusion of blood through an adsorbent column. The clinical effects of hemoperfusion relate to the AC adsorptive capacity, and any inflammatory response generated by direct blood contact

10 May 2017 in Biomedical Materials
Verified
Journal Article
Open access
PDF file
SSSusan R. Sandeman
Susan R. Sandeman
YZYishan Zheng
Yishan Zheng
GIGanesh C Ingavle
Ganesh C Ingavle
CHCarol A Howell
Carol A Howell
SMSergey Mikhalovsky
Sergey Mikhalovsky
NDNathan Davies
Nathan Davies
Nanoporous adsorbents are promising materials to augment the efficacy of haemodialysis for the treatment of end stage renal disease where mortality rates remain unacceptably high despite improvements in membrane technology. Complications are linked in part to inefficient removal of protein bound and high molecular weight uraemic toxins including key marker molecules albumin bound indoxyl sulphate (IS) and p-cresyl sulphate (PCS) and large inflammatory cytokines such as IL-6. The following study describes the assessment of a nanoporous activated carbon monolith produced using a novel binder synthesis route for scale up as an in line device to augment haemodialysis through adsorption of these toxins. Small and large monoliths were synthesised using an optimised ratio of lignin binder to porous resin of 1 in 4. Small monoliths showing combined significant IS, p-CS and IL-6 adsorption were used to measure haemocompatibility in an ex vivo healthy donor blood perfusion model, assessing coagulation, platelet, granulocyte, T cells and complement activation, haemolysis, adsorption of electrolytes and plasma proteins. The small monoliths were tested in a naive rat model and showed stable blood gas values, blood pressure, blood biochemistry and the absence of coagulopathies. These monoliths were scaled up to a clinically relevant size and were able to maintain adsorption of protein bound uraemic toxins IS, PCS and high molecular weight cytokines TNF-α and IL-6 over 240 min using a flow rate of 300 ml min-1 without platelet activation. The nanoporous monoliths where haemocompatible and retained adsorptive efficacy on scale up with negligible pressure drop across the system indicating potential for use as an in-line device to improve haemodialysis efficacy by adsorption of otherwise poorly removed uraemic toxins.